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We analysed the expression of activated (phosphorylated) Akt and MAPK in 98 cases of paired primary colorectal tumours and
metastases with the aim to define better the epidermal growth factor receptor (EGFR)-related molecular profile of colorectal cancer
as a tool for treatment selection. Among 47 (48%) EGFR-negative primary tumours, 35 cases (74%) were positive for phosphorylated
Akt and MAPK. Among 51 (52%) EGFR-positive primary colorectal cancers, 13 (25%) cases were negative for phosphorylated Akt
and 15 (29%) were negative for phosphorylated MAPK. In EGFR-negative metastases (56 cases, 55%), phosphorylated Akt was
expressed in 41 (73%) and phosphorylated MAPK was expressed in 36 (64%) samples, whereas in EGFR-positive metastases,
phosphorylated Akt and MAPK were negative in 14 (31%) and in 10 (22%) cases, respectively. Phosphorylated Akt expression in
primary colorectal tumours changed from positive to negative in 16 (16%) paired metastases and from negative to positive in 13
(13%) related metastatic sites. Phosphorylated MAPK expression in primary tumours changed from positive to negative in 13 (13%)
paired metastases and from negative to positive in 12 (12%) related metastatic sites. Our findings suggest that phosphorylated Akt
and MAPK status in primary tumours does not correlate with Akt and MAPK status in corresponding metastases. EGFR downstream
signalling pathway can be overactivated even in the absence of EGFR expression in a considerable proportion of patients.
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The epidermal growth factor receptor (EGFR) is a tyrosine kinase
protein, which plays an important role both in the signal
transduction pathway and cellular function (Carpenter and Cohen,
1990).
Binding of specific ligand, such as the epidermal growth factor
(EGF) and transforming growth factor a (TGF-a) to the EGFR,
results in the dimerisation of the receptor with the subsequent
initiation of the intracellular signalling pathways cascade. A major
downstream signalling route is via the Ras-Raf-MAPK. Activation
of Ras initiates a multistep phosphorylation cascade that leads
to the activation of MAPKs, ERK1 and ERK2, which ultimately
regulate transcription of molecules involved in cell proliferation
(Mendelsohon and Baselga, 2003). Another important target in
EGFR signalling is phosphatidylinositol 3-kinase (P13K) and the
downstream protein-serine/threonine kinase Akt. This latter
protein kinase transduces molecular signals triggering crucial
steps for cell growth and survival (Carpenter and Cohen, 1990;
Mendelsohon and Baselga, 2003).
The demonstration that EGFR results abnormally expressed or
upregulated in 50–80% of all cases of advanced colorectal tumours
(Hemming et al, 1992; Kluftinger et al, 1992; Mayer et al, 1993)
brought to the active development of anti-EGFR treatment
strategies for these patients, including monoclonal antibodies,
which target the extracellular domain of the EGFR and small
molecules (tyrosine kinase inhibitors, TKIs), which target the
tyrosine kinase domain of the receptor. Although multiple
therapeutic options targeting the EGFR molecular pathway have
been proposed, the biologic mechanisms underlying the activity of
these drugs ‘in vivo’ are still to be investigated fully.
Clinical studies demonstrated that EGFR expression is not to be
considered as a predictive marker for such treatment strategies;
therefore, it has been postulated that the activation of the
downstream signalling pathway (Akt and MAPK) could be
responsible for EGFR aberrant activity even in the absence of a
detectable EGFR expression (Cunningham et al, 2004; Ellis and
Hoff, 2004; Saltz et al, 2004; Fischel et al, 2005). In this case,
targeting the receptor via monoclonal antibodies would probably
be clinically irrelevant, whereas it would be more appropriate an
attempt to block intracitoplasmic tyrosine kinase activity via small
molecules inhibiting the tyrosine kinase portion of the EGFR. In
fact, in non-small-cell lung cancer patients, it has been suggested
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sthat TKIs’ responsiveness might be predicted by EGFR down-
stream proteins such as activated (phosphorylated) Akt (Cappuzzo
et al, 2005; Han et al, 2005). However, data regarding the in vivo
EGFR-driven molecular profile in colorectal cancer are conflicting
and consequently, at present, no speculations are possible about its
role in determining resistance or sensitivity to EGFR-targeted
drugs.
Recently in a series of 28 advanced colorectal patients treated
with gefitinib monotherapy, biologic evaluation of total and
activated EGR, activated Akt, MAPK and Ki 67 on paired pre-
and 1-week post-treatment tumour samples could not confirm a
gefitinib-induced decreased expression of these molecular markers
(Rothenberg et al, 2005).
However, these data does not seem to be concordant with those
reported in a similar analysis by Daneshmand et al (2003) although
in a smaller series.
After our previous finding of a substantial lack of correlation for
EGFR status between primary colorectal tumours and correspond-
ing metastases (Scartozzi et al, 2004), it has been suggested that the
possibility for an appropriate anti-EGFR treatment selection could
be highly dependent on the actual presence and activation of
the target itself. We then analysed the expression of activated
(phosphorylated) Akt and MAPK in primary tumours and
corresponding metastatic sites with an already known EGFR
status, with the aim to define better the EGFR-related molecular
profile of colorectal cancer, to serve as a tool for treatment
selection.
PATIENTS AND METHODS
Patient selection
Patients were selected from a pathological database of colorectal
cancer cases, who underwent surgical resection of the primary
tumour and the corresponding metastatic site, observed at the
Pathology Department of the Universita ` Politecnica delle Marche,
Ancona, Italy, between 1995 and 2005.
Immunohistochemical analysis
The expression of phospho-Akt (Ser437), p44/42 MAP kinase (Cell
Signaling Technology, MA, USA) and EGFR (Dako Cytomation,
CA, USA) was evaluated with an immunohistochemistry technique
on 5-mm-thick tissue section obtained from paraffin-embedded
specimens fixed in 10% (vv
 1) neutral buffered formalin.
The sections were deparaffinised and hydrated by passing
through xylene and a graded series of ethanol, followed by washing
in distilled water.
The antigens were unmasked for phospho-Akt (Ser437) by heat
treatment at 981C for 10min, in EDTA buffer and for p44/42 MAP
kinase by microwave treatment at 981C for 10min, in a 10mM
citrate buffer, pH 6.0. After antigens retrieval, tissues were blocked
with 5% normal goat serum for 60min.
Subsequently, the sections were incubated either with phospho-
Akt (Ser437) antibody (1:50 dilution) or MAP kinase antibody
(1:100 dilution) overnight at 41C.
Consecutively, immunostaining was performed by the avidin–
biotin peroxidase complex technique (Dako Envision System, CA,
USA) for 30min according to the manufacturer’s instructions
and using 30,30 diaminobenzidine (DAB, Dako Cytomation) as a
chromogen. Subsequently, the slides were counterstained with
Meyer’s haematoxylin for 1min, dehydrated in a graded series of
alcohol, treated with xylene and cover slipped.
Positive control of phospho-Akt (Ser437) and p44/42 MAP
kinase staining was performed on paraffin-embedded human
breast cancer in all runs. (Data Sheet of phospho-Akt (Ser437) and
p44/42 MAP kinase antibodies, Cell-Signalling Technology.)
Negative control for the validation of the phospho-Akt (Ser437),
p44/42 MAP kinase assay consisted of sections incubated with
secondary antibody alone without primary antibody in all runs.
(Data Sheet of phospho-Akt (Ser437) and p44/42 MAP kinase
antibodies; Cell Signaling Technology.)
All slides were evaluated independently by two pathologists (IB
and AM).
Evaluation of EGFR expression
Epidermal growth factor receptor expression was detected as
membranous or cytoplasmic brown staining of neoplastic cells
with various intensity. Positivity for EGFR expression was defined
as any membrane staining above background level, whether or not
completely circumferential. In each case, two stained sections of
the tumours were quantified by light microscopy, and a score
(range 0–100) expressing the percentage of positive neoplastic
cells was obtained.
Both the primary and metastatic neoplasm were considered
positive when more than 1% of the tumour cells had membranous-
complete or -incomplete staining; the neoplasms that showed a
specific membrane staining lower than 1% of neoplastic cells were
defined negative.
The cytoplasmic staining, resulting from either internalised or
nascent receptor molecules, without associated membrane staining
was reported as negative.
The intensity of EGFR reactivity was scored using a three-tier
system:
  1þ weak intensity: faint brown membranous staining;
  2þ moderate intensity: brown membranous staining of
intermediate darkness producing a complete or incomplete
circular outline of the neoplastic cell;
  3þ strong intensity: dark brown or black membranous staining
producing a thick outline, complete or incomplete of the
neoplastic cell.
The percentage of the cells for each intensity staining (1þ;2þ;
3þ) was obtained when the intensity EGFR stain was hetero-
geneous (Scartozzi et al, 2004).
Evaluation of phospho-Akt (Ser473) expression
Phospho-Akt expression was detected as cytoplasmic and nuclear
staining of neoplastic cells with various intensity. The intensity
of phospho-Akt (Ser473) reactivity was scored using a four-tier
system: 0, no staining; 1, weak; 2, moderate; and 3, strong.
Positivity for expression of phospho-Akt (Ser473) was defined as
cytoplasmatic staining, with score 2 and/or 3; negativity with score
0 and/or 1. Both the primary and metastatic neoplasm were
considered positive when more than 1% of the tumour cells had
score 2 and/or 3 (Roy et al, 2002).
Evaluation of p44/42 MAP kinase expression
p44/42 MAP kinase expression was detected as cytoplasmic
with nuclear brown staining of neoplastic cells. The intensity
of p44/42 MAP kinase reactivity was scored using a four-tier
system as follows: 0, no staining; 1, weak; 2, moderate and 3,
strong. The proportion of neoplastic cells showing a positive
signal was scored by assessing on a scale of 0–1: 0, none; 0.1, less
than one-tenth; 0.5, less than one-half and 1.0, greater than one-
half. The intensity and proportion scores were then multiplied to
give an H-score; tumours with a score equal to or higher than
1.0 were deemed positive (Adeyinka et al, 2002; Al-haddad et al,
2005).
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Ninety-eight patients were available for our analysis: 61 (62%) men
and 37 (38%) women, median age at diagnosis was 63 (range 32–
86) years. Seventy-four (75%) patients had colon and 24 (25%) had
rectal cancer. Colorectal adenocarcinoma was the most common
histological type as it was observed in 92 (94%) pathological
samples from primary tumours; the remaining six (6%) cases
were mucinous adenocarcinomas. Histology grades 1–2 and 3
were described in 83 (85%) and 15 (15%) tumours, respectively. In
95 cases of primary neoplasm, only a single metastatic site (97%)
was available for analysis, three cases had both pulmonary and
hepatic metastases (3%) (Table 1).
Globally, pathologic samples from 101 metastatic sites were
analysed: 84 (83%), liver metastases; 12 (12%), lung metastases; 4
(4%), brain and 1 (1%) bone metastases (Table 1).
All metastatic samples were obtained from metastasectomies
except for the only bone metastasis, which was a biopsy. Liver
metastases were synchronous in 42 cases and metachronous in the
remaining 41 cases. Seven lung metastases were synchronous,
whereas the remaining five were metachronous as they were all
brain lesions (four cases). Therefore, globally in 49 cases (50%),
the metastatic site analysed was synchronous. The median time
elapsed between resection of the primary and corresponding
metastatic site was 9 months.
In 38 cases (39%), surgical resection of metastases (and
consequently specimens collection) was performed after the
administration of chemotherapy.
Epidermal growth factor receptor expression was positive in 51
(52%) primary tumours and 45 (45%) metastatic sites (Table 2).
In primary tumours phosphorylated Akt and MAPK were
positive in 73 (74%) and 71 (70%) cases, respectively, whereas
phosphorylated Akt and MAPK were positive in 72 (73%) and 71
(70%) metastatic sites, respectively (Table 2).
Among 47 (48%) EGFR-negative primary tumours, 35 cases
(74%) expressed phosphorylated Akt and MAPK (Figure 1). On the
contrary, among 51 (52%) EGFR-positive primary colorectal
cancers, 13 (25%) cases were negative for phosphorylated Akt
and 15 (29%) were negative for phosphorylated MAPK (Table 3)
(Figure 2).
Similar to these findings, also in EGFR-negative metastases (56
cases, 55%), phosphorylated Akt was expressed in 41 (73%) and
MAPK was expressed in 36 (64%) samples, whereas in EGFR-
positive metastases phosphorylated Akt was negative in 14 (31%)
cases and MAPK was negative in 10 (22%) cases (Table 4).
Phosphorylated Akt expression in primary colorectal tumours
changed from positive to negative in 16 (16%) paired metastases
and from negative to positive in 13 (13%) related metastatic sites.
Table 1 Patients’ characteristics
No. of patients (N¼98) (%)
Age (years)
Median 63
Range 32–86
Sex
Male 61 62
Female 37 38
Primary tumour location
Colon 74 75
Rectum 24 25
Primary tumour characteristics
Adenocarcinoma 92 94
Mucinous 6 6
Gradings 1–2 83 85
Grading 3 15 15
Metastatic sites analysed 101
Liver 84 83
Lung 12 12
Brain 4 4
Bone 1 1
A B
Figure 1 (A) Primary colorectal tumour showing membranous EGFR-negative staining; (B) primary colorectal tumour with positive cytoplasmic (arrow)
and nuclear (head of the arrow) phosphorylated MAPK staining.
Table 2 Global results for EGFR, Akt and MAPK expression
Primary tumour (%) Liver metastases (%) Lung metastases (%) Brain metastases (%) Bone metastasis (%)
EGFR
Positive 51 (52) 39 (48) 5 (42) 1 (25) 0 (0)
Negative 47 (48) 45 (52) 7 (58) 3 (75) 1 (100)
Akt
Positive 73 (74) 61 (73) 5 (42) 4 (100) 1 (100)
Negative 25 (26) 23 (27) 7 (58) 0 (0) 0 (0)
MAPK
Positive 71 (70) 62 (74) 8 (67) 0 (0) 1 (100)
Negative 27 (30) 22 (26) 4 (33) 4 (100) 0 (0)
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colorectal tumours
Akt MAPK
Positive (%) Negative (%) Positive (%) Negative (%)
EGFR
Positive 38 (75) 13 (25) 36 (70) 15 (30)
Negative 35 (75) 12 (25) 35 (75) 12 (25)
AB
Figure 2 (A) Primary colorectal tumour showing membranous EGFR-positive staining with strong intensity (3þ); (B) primary colorectal tumour with
negative phosphorylated MAPK staining.
Table 4 Akt and MAPK status according to EGFR expression in
metastases
Akt MAPK
Positive (%) Negative (%) Positive (%) Negative (%)
EGFR
Positive 31 (69) 14 (31) 35 (78) 10 (22)
Negative 41 (73) 15 (27) 36 (64) 20 (36)
Table 5 Akt and MAPK status variations between primary tumour and the corresponding metastatic sites
Akt status variation MAPK status variation
Metastatic sites Positive to negative Negative to positive Positive to negative Negative to positive
Liver 12 7 9 8
Lung 4 1 2 4
Brain 0 3 2 0
Bone 0 1 0 0
Total 16 (16%) 13 (13%) 13 (13%) 12 (12%)
A B
C D
Figure 3 (A) Primary colorectal tumour showing positive cytoplasmic (arrow) and nuclear (head of the arrow) phosphorylated MAPK staining; (B)
corresponding liver metastasis with negative phosphorylated MAPK staining. (C) Primary colorectal tumour showing positive cytoplasmic phosphorylated
Akt staining (arrow); (D) corresponding liver metastasis with negative phosphorylated Akt staining.
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changed from positive to negative in 13 (13%) paired metastases
and from negative to positive in 12 (12%) related metastatic sites
(Table 5) (Figure 3). Interestingly, in all three cases with two
metastatic sites available for analysis (liver and lung), we observed
a variation for MAPK expression between the two different
metastatic sites.
Among the group of patients receiving chemotherapy before
resection of metastases, we observed a shift in phosphorylated Akt
and MAPK expression in six and four cases, respectively.
DISCUSSION
The introduction of a novel class of targeted antineoplastic
agents, such as those directed against the EGFR, have notably
expanded the available therapeutic options for patients with
advanced colorectal cancer (Cunningham et al, 2004; Ellis and
Hoff, 2004).
Unfortunately, available clinical data generally failed to demon-
strate a correlation between the level of expression of the target
(EGFR in this case) and the global outcome of patients treated,
thus making the need for a reliable predictive factor for
pretreatment selection of patients as potential candidates to
EGFR-targeted therapies even more relevant (Cunningham et al,
2004; Ellis and Hoff, 2004; Saltz et al, 2004). Furthermore, we
are unable both to select appropriately patients for an anti-EGFR
treatment, and to define which treatment would be better (i.e.
monoclonal antibodies or TKI) for our patient. The present
analysis is based on the hypothesis that an appropriate anti-EGFR
treatment selection could be dependent on the actual presence and
activation of the target itself. We then analysed the expression of
activated (phosphorylated) Akt and MAPK in primary tumours
and the corresponding metastatic sites with an already known
EGFR status, with the aim to define better the EGFR-related
molecular profile of colorectal cancer, to serve as a tool for
treatment selection.
One of the main results of our study was the observation that
Akt and MAPK expression could be independent of EGFR status
both in primary and metastatic sites, thus suggesting that EGFR
downstream signalling pathway can be overactivated even in the
absence of EGFR expression in a non-negligible proportion of
patients. Consequently, the use of anti-EGFR treatment with
monoclonal antibodies could be at least theoretically inappropriate
in these tumours, whereas the use of a treatment strategy including
TKIs that can interfere with the EGFR downstream pathway could
be more appealing. However, these latter assumptions should be
considered purely speculative, as in our analysis we did not include
information about other biological determinants, such as EGFR
mutations or abnormal expression of other EGFR-driven down-
stream molecules, which may play a relevant role in EGFR-directed
treatment selection.
However, our observation seems to be similar to results reported
by Rothenberg et al (2005), in which they were not able to confirm
a correlation between the inhibition of Akt and MAPK and
response to an EGFR TKI (gefitinib) in colorectal cancer, but
suggested a definite trend for inhibition of the EGFR-driven
activation of downstream regulators in patients achieving a longer
progression-free survival. These results should be considered even
more relevant if we consider that the timing adopted for tumour
biopsies collection for biological studies could have been not
optimal.
Similar to our previous findings of a substantial lack of
correlation for EGFR status between primary colorectal tumours
and corresponding metastases (Scartozzi et al, 2004), we also
noticed a substantial variation for Akt and MAPK expression
among primary tumours and related metastases.
This implies that this biological phenomenon could account for
resistance to antineoplastic treatment directed against the EGFR,
if we assume that the loss of the target should render ineffective
any therapy directed against it. However, we should also consider
that the staining methods currently used for EGFR expression
could be considered inadequate as a predictive tool for anti-EGFR
treatment strategies and may be primarily responsible for the
apparent lack of association between EGFR positivity and response
to treatment.
The observation that in 49 cases (50%), metastases were
metachronous seems also to suggest the hypothesis that changes
in phosphorylated Akt and MAPK expression could have occurred
over time with progression of disease. Among patients receiving
chemotherapy before specimens collection (38 cases, 39%), it is
important to note that phosphorylated Akt and MAPK variation
might be hypothetically related to a ‘selective’ effect of the
treatment. Nevertheless, the number of cases observed (six cases
for Akt and four cases for MAPK variation) does not seem to
confirm this assumption.
As EGFR-targeted treatment strategies are employed to treat
metastatic disease on the basis of our data, only the EGFR-
downstream signalling pathway status in metastases would be
relevant. Nevertheless, only a prospective trial including biological
assessment of these parameters on metastases could definitely
establish whether this could be considered effective in the clinical
practice.
Taken together, we believe that our observations could bring
further insights into the biology of EGFR-expressing colorectal
tumours and along with growing clinical data could help clinicians
in the future to select better the appropriate anti-EGFR treatment
option for the appropriate patient.
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